Novo Nordisk Stock Drops 11% After Alzheimer’s Drug Trial Failure

Novo Nordisk (NVO) stock shares collapsed 11% on November 24th after the company announced its Evoke Phase 3 trials failed to demonstrate a statistically significant reduction in Alzheimer’s disease progression using semaglutide (Wegovy/Ozempic). The setback marks a critical blow to Novo’s ambitions to expand its blockbuster GLP-1 franchise beyond obesity and diabetes. HSBC immediately downgraded the stock from Buy to Hold following the news.

Key Drivers of the NVO Stock Move

• Summary of Main Catalyst: Novo’s Evoke Phase 3 trial data showed semaglutide failed to slow cognitive decline in Alzheimer’s patients, shattering hopes that GLP-1 drugs could address neurodegenerative diseases. This comes despite earlier encouraging weight loss data showing 21% body weight reduction with higher Wegovy doses and positive cardiovascular markers.
• Bull Case: Novo recently struck a deal with the Trump administration to offer obesity drugs at $149 monthly, potentially unlocking massive Medicare coverage expansion starting in 2026. The company beat Q3 earnings expectations significantly (EPS $1.03 vs. $0.77 estimate), raising guidance for 8% to 11% sales growth. Management announced expanded telehealth access for obesity care and aggressive pricing strategies, including $199 promotional pricing through March 2026. Additionally, Novo’s pipeline remains robust, with investigational CagriSema showing promising blood pressure reductions.
• Bear Case: Beyond the Alzheimer’s failure, Novo faces intensifying competition from Pfizer and Eli Lilly in the obesity market, evidenced by the bidding war over Metsera (which Pfizer won at $10 billion). The FTC raised antitrust concerns about Novo’s acquisition strategy. Management noted growth deceleration toward year-end, and the stock has declined 20% from October peaks. Quarterly relative strength versus healthcare peers dropped from the 50th percentile in early November to the 35th percentile currently.

The confluence of pipeline setbacks, competitive pressures, and valuation compression creates significant headwinds despite positive pricing developments and Medicare access expansion.

NVO Smart Money Activity

Congressional trading showed modest Republican buying throughout August through October, with Rep. Marjorie Taylor Greene making multiple purchases between $15K and $50K. However, all these trades are currently underwater, showing losses ranging from 7% to 17%. No insider trading data was available for the period, suggesting management may be restricted or cautious.

NVO Unusual Options

Options flow turned decisively bearish following the trial news. On November 20th, before the announcement, bullish June 2026 $60 calls dominated with $190K premiums. Post-collapse on November 24th, activity shifted dramatically to protective puts and bearish spreads. Notable trades included $425K in September 2026 $40 puts (bullish positioning for a bounce) and $457K in bearish March 2026 $50 calls sold. The heaviest volume concentrated in January 2026 $45 calls, suggesting traders expect range-bound action near current levels through year-end.

NVO Seasonality

Historical data since November 2015 (11 samples) shows November is typically positive with a 64% win rate and an average gain of 1.8%. However, December has been Novo’s strongest month historically at 80% positive with 1.8% average gains. August and May have shown the best seasonal strength (70% positive, 4.3% and 2.5% gains, respectively), while September has been consistently weak (only 20% positive, average decline of 3.8%).

NVO Analyst Focus

• Recent Upgrades: Berenberg upgraded to Buy on September 17th, and HSBC upgraded to Buy with a $70 target on October 2nd (before quickly reversing course).
• Recent Downgrades: Morgan Stanley downgraded to Sell with a price target cut from $59 to $47 on September 29th. Jefferies initiated coverage with a Sell on October 27th. HSBC reversed to Hold on November 24th following a trial failure.
• Median Price Target: Approximately $55, suggesting 22% upside from current levels, though targets likely require downward revision following the Alzheimer’s setback.